VaccinesArchives
Can vaccine-preventable disease resurgence be anticipated? Leading indicators and tipping points
Vaccines 1 min.
Vaccination programs have averted millions of childhood deaths, yet vaccine-preventable diseases (VPDs) continue to resurge as coverage declines and pathogen evolution undermines previously successful vaccines. Anticipating resurgence is a public health priority. We review theoretical and empirical advances...
Loss of confidence in vaccines following media reports of infant deaths after hepatitis B vaccination in China
Vaccines 1 min.
China reduced hepatitis B virus (HBV) infection by 90% among children under 5 years old with safe and effective hepatitis B vaccines (HepB). In December 2013, this success was threatened by widespread media reports of infant deaths following HepB administration. Seventeen deaths and one case of anaphylactic...
COVID-19 burden in the paediatric population in Latin America during vaccine rollout: a real-world study using national surveillance data
Vaccines 6 min.
Coronavirus disease 2019 (COVID-19) has impacted the health and well-being of children and adolescents worldwide [1]. Although COVID-19 generally has a milder presentation in the paediatric population, severe outcomes, including hospitalisation and death, can still occur, especially among those with...
Vaccine adjuvants as stand-alone immunoprophylaxis in strategies for 100-day rapid responses to future pandemics
Vaccines 1 min.
The COVID-19 pandemic accelerated vaccinology progress, driving rapid vaccine development for infectious and non-infectious diseases. However, challenges persist: malaria, HIV, and dengue lack fully effective vaccines, whereas influenza and tuberculosis face waning efficacy. Emerging pathogens and drug-resistant...
Imprecision in tuberculosis infection outcomes: implications for non-inferiority vaccine trials
Vaccines 1 min.
Randomized trials comparing new vaccines against tuberculosis for use in neonates and infants, for whom Bacille Calmette-Guérin vaccination is established practice, are using tuberculosis infection as the primary endpoint in a non-inferiority design. Markers of tuberculosis infection have imperfect...
